Clinofibrate

CAS : 30299-08-2

Ref. 3D-FC20487

Informations sur le produit

• Nom: Clinofibrate
• Synonymes: 1,1-Bis[4'-(1''-carboxy-1''-methylpropoxy)phenyl]cyclohexane2,2'-[Cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-butanoic acidL ipoclin, 1,1-Bis[4'-(1''-carboxy-1''-methylpropoxy)phenyl]cyclohexane, 2,2'-(Cyclohexylidenebis(4,1-Phenyleneoxy))Bis(2-Methyl)-Butanoic Acid, 2,2'-[Cyclohexane-1,1-Diylbis(Benzene-4,1-Diyloxy)]Bis(2-Methylbutanoic Acid), 2,2’-(4,4’-Cyclohexylidenediphenoxy)-2,2’-Dimethyldibutyricacid, 2,2’-Cyclohexane-1,1-Diylbis(P-Phenyleneoxy)Bis(2-Methylbutyricacid), 2,2’-Cyclohexane-1,1-Diylbis(P-Phenyleneoxy)Bis-(2-Methyl-Butyricaci, 2,2′-[Cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methylbutanoic acid], Butanoic acid, 2,2′-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-, Clinofibrate(Forr&Donly), Lipoclin, S 8527
• CAS: 30299-08-2

Description

Clinofibrate is a hypolipidemic agent that is used to lower serum cholesterol levels. It is a prodrug that is converted to its active form, clofibrate, in the liver. Clinofibrate inhibits hydroxylation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is involved in the synthesis of cholesterol. Clinofibrate also has been shown to reduce atherosclerotic plaque formation in animal models and has been shown to have pharmacokinetic properties similar to those of other hypolipidemic agents.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 468.58 g/mol
• Formule: C₂₈H₃₆O₆
• Degré de pureté: Min. 95%